CoChat
Sign Up
Cited by 119

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Immune checkpoint inhibitors in cancer therapy

Eika, S., Peng, Liu, Renato, Baleeiro, Nicholas, R., Ming, Yuan, Yaohe, Wang·2018·The Journal of Biomedical Research
DOI 10.7555/jbr.31.20160168PMC PMC6163118
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7555/jbr.31.20160168

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Rationale for the use of immune checkpoint inhibitors in cancer therapy.
Fig.1 Rationale for the use of immune checkpoint inhibitors in cancer therapy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 84

  1. [1]Page DB, Postow MA, Callahan MK, Immune modulation in cancer with antibodies[J]. Annu Rev Med, 2014, 65: 185– 202. 24188664
  2. [2]Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252– 264. 22437870 PMC4856023
  3. [3]Burnet M. Cancer; a biological approach. I. The processes of control[J]. Br Med J, 1957, 1(5022): 779– 786. 13404306 PMC1973174
  4. [4]Sakaguchi S, Miyara M, Costantino CM, FOXP3+ regulatory T cells in the human immune system[J]. Nat Rev Immunol, 2010, 10(7): 490– 500. 20559327
  5. [6]Kryczek I, Zou L, Rodriguez P, B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma[J]. J Exp Med, 2006, 203(4): 871– 881. 16606666 PMC2118300
  6. [8]Cui TX, Kryczek I, Zhao L, Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2[J]. Immunity, 2013, 39(3): 611– 621. 24012420 PMC3831370
  7. [11]Galon J, Costes A, Sanchez-Cabo F, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795): 1960– 1964. 17008531
  8. [12]Kryczek I, Zhao E, Liu Y, Human TH17 cells are long-lived effector memory cells[J]. Sci translat med, 2011; 3: 104ra0. PMC3345568 21998407
  9. [14]Chen L, Linsley PS, Hellström KE. Costimulation of T cells for tumor immunity[J]. Immunol Today, 1993, 14(10): 483– 486. 7506034
  10. [15]Tivol EA, Borriello F, Schweitzer AN, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4[J]. Immunity, 1995, 3(5): 541– 547. 7584144
  11. [16]Nishimura H, Okazaki T, Tanaka Y, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice[J]. Science, 2001, 291(5502): 319– 322. 11209085
  12. [17]Nishimura H, Nose M, Hiai H, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J]. Immunity, 1999, 11(2): 141– 151. 10485649
  13. [19]Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses[J]. Curr Opin Immunol, 1995, 7(5): 682– 686. 8573312
  14. [21]Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J]. N Engl J Med, 2016, 375(18): 1767– 1778. 27806234 PMC5575761
  15. [22]Dong H, Zhu G, Tamada K, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12): 1365– 1369. 10581077
  16. [23]Tseng SY, Otsuji M, Gorski K, B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells[J]. J Exp Med, 2001, 193(7): 839– 846. 11283156 PMC2193370
  17. [24]Freeman GJ, Long AJ, Iwai Y, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7): 1027– 1034. 11015443 PMC2193311
  18. [26]Butte MJ, Keir ME, Phamduy TB, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27(1): 111– 122. 17629517 PMC2707944
  19. [28]Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next[J]? Curr Opin Immunol, 2015, 33: 23– 35. 25621841
  20. [29]Aldarouish M, Wang C. Trends and advances in tumor immunology and lung cancer immunotherapy[J]. Journal of experimental & clinical cancer research: CR. 2016; 35: 157. 27686848 PMC5043622
  21. [30]Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited[J]. Annu Rev Immunol, 2005, 23: 515– 548. 15771580
  22. [31]Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science, 1996, 271(5256): 1734– 1736. 8596936
  23. [32]Erfani N, Mehrabadi SM, Ghayumi MA, Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2012, 77(2): 306– 311. 22608141
  24. [33]Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment[J]. Cell Death Dis, 2015, 6: e1792. 26086965 PMC4669840
  25. [34]Funt SA, Page DB, Wolchok JD, CTLA-4 antibodies: new directions, new combinations[J]. Oncology (Williston Park), 2014, 28(Suppl 3): 6– 14. 25387681
  26. [35]Li L, Chao QG, Ping LZ, The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC[J]. Cancer Biother Radiopharm, 2009, 24(3): 357– 367. 19538059
  27. [37]Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest, 2015, 125(9): 3384– 3391. 26325035 PMC4588282
  28. [38]Sauce D, Almeida JR, Larsen M, PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status[J]. AIDS, 2007, 21(15): 2005– 2013. 17885290
  29. [39]Liang SC, Latchman YE, Buhlmann JE, Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol, 2003, 33(10): 2706– 2716. 14515254
  30. [40]Thompson RH, Gillett MD, Cheville JC, Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target[J]. Proc Natl Acad Sci U S A, 2004, 101(49): 17174– 17179. 15569934 PMC534606
  31. [43]Wu C, Zhu Y, Jiang J, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance[J]. Acta Histochem, 2006, 108(1): 19– 24. 16530813
  32. [44]Nomi T, Sho M, Akahori T, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2007; 13: 2151– 2157. 17404099
  33. [45]Brown JA, Dorfman DM, Ma FR, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production[J]. J Immunol, 2003, 170(3): 1257– 1266. 12538684
  34. [46]Konishi J, Yamazaki K, Azuma M, B7–H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2004; 10: 5094– 5100. 15297412
  35. [47]Liu J, Hamrouni A, Wolowiec D, Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway[J]. Blood, 2007, 110(1): 296– 304. 17363736
  36. [48]Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy[J]. FEBS Lett, 2014, 588(2): 368– 376. 24161671
  37. [50]Hodi FS, O’Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711– 723. 20525992 PMC3549297
  38. [52]Kwon ED, Hurwitz AA, Foster BA, Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer[J]. Proc Natl Acad Sci U S A, 1997, 94(15): 8099– 8103. 9223321 PMC21563
  39. [53]Van Ginderachter JA, Liu Y, Geldhof AB, B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma[J]. Int J Cancer, 2000, 87(4): 539– 547. 10918195
  40. [54]Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer[J]. Scand J Immunol, 2010, 71(2): 70– 82. 20384858
  41. [56]Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4[J]. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 5238– 42. 17875750
  42. [57]Boasberg P, Hamid O, O’Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade[J]. Semin Oncol, 2010, 37(5): 440– 449. 21074058
  43. [58]Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab[J]. Semin Oncol, 2010, 37(5): 450– 454. 21074059
  44. [59]Sondak VK, Smalley KS, Kudchadkar R, Ipilimumab[J]. Nat Rev Drug Discov, 2011, 10(6): 411– 412. 21629286
  45. [60]Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443– 2454. 22658127 PMC3544539
  46. [61]Prieto PA, Yang JC, Sherry RM, CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2012; 18: 2039– 2047. 22271879 PMC3319861
  47. [62]Thompson JA, Hamid O, Minor D, Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial[J]. J Immunother, 2012, 35(1): 73– 77. 22130164
  48. [63]Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment[J]. Nat Rev Cancer, 2012, 12(4): 237– 251. 22437869 PMC3967236
  49. [64]Schadendorf D, Hodi FS, Robert C, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma[J]. J Clin Oncol, 2015, 33(17): 1889– 1894. 25667295 PMC5089162
  50. [65]Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 2012, 366(26): 2455– 2465. 22658128 PMC3563263
  51. [66]Brahmer JR, Drake CG, Wollner I, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167– 3175. 20516446 PMC4834717
  52. [67]Lipson EJ, Sharfman WH, Drake CG, Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2013; 19: 462– 468. 23169436 PMC3548952
  53. [68]Li B, VanRoey M, Wang C, Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors[J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2009; 15: 1623– 1634. 19208793
  54. [69]Soares KC, Rucki AA, Wu AA, PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors[J]. J Immunother, 2015, 38(1): 1– 11. 25415283 PMC4258151
  55. [70]Robert C, Ribas A, Wolchok JD, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial[J]. Lancet, 2014, 384(9948): 1109– 1117. 25034862
  56. [72]Ascierto PA, Marincola FM. 2015: The Year of Anti-PD-1/PD-L1s Against melanoma and beyond[J]. EBio Medicine, 2015, 2(2): 92– 93. 26137543 PMC4485477
  57. [73]Powles T, Eder JP, Fine GD, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer[J]. Nature, 2014, 515(7528): 558– 562. 25428503
  58. [76]Armand P, Nagler A, Weller EA, Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial[J]. J Clin Oncol, 2013, 31(33): 4199– 4206. 24127452 PMC4878008
  59. [77]Westin JR, Chu F, Zhang M, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial[J]. Lancet Oncol, 2014, 15(1): 69– 77. 24332512 PMC3922714
  60. [78]Ansell SM, Lesokhin AM, Borrello I, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma[J]. N Engl J Med, 2015, 372(4): 311– 319. 25482239 PMC4348009
  61. [79]Hamid O, Robert C, Daud A, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med, 2013, 369(2): 134– 144. 23724846 PMC4126516
  62. [80]Topalian SL, Sznol M, McDermott DF, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol, 2014, 32(10): 1020– 1030. 24590637 PMC4811023
  63. [84]Weber JS, D’Angelo SP, Minor D, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 375– 384. 25795410
  64. [87]Gettinger SN, Horn L, Gandhi L, Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2015, 33(18): 2004– 2012. 25897158 PMC4672027
  65. [89]McDermott DF, Drake CG, Sznol M, Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab[J]. J Clin Oncol, 2015, 33(18): 2013– 2020. 25800770 PMC4517051
  66. [90]Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer[J]. Clin Pharmacol Ther, 2014, 96(2): 214– 223. 24690569 PMC5685326
  67. [92]Mangsbo SM, Sandin LC, Anger K, Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy[J]. J Immunother, 2010, 33(3): 225– 235. 20445343
  68. [93]Raval RR, Sharabi AB, Walker AJ, Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer[J]. J Immunother Cancer, 2014, 2: 14. 24883190 PMC4039332
  69. [94]Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence[J]. Onco Targets Ther, 2014, 7: 1349– 1359. 25114573 PMC4122552
  70. [95]Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol, 2013, 5(3): 169– 181. 23634195 PMC3630481
  71. [96]Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer[J]. Oncoimmunology, 2014, 3: e29288. 25083339 PMC4106164
  72. [97]Brahmer JR, Topalian S, Wollner I, Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies[J]. J Clin Oncol, 2008, 26: 3006. 18458044
  73. [98]Swart M, Verbrugge I, Beltman JB. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy[J]. Front Oncol, 2016, 6: 233. 27847783 PMC5088186
  74. [99]Naidoo J, Page DB, Li BT, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2015; 26: 2375– 2391. 26371282 PMC6267867
  75. [100]Alexandrov LB, Nik-Zainal S, Wedge DC, Signatures of mutational processes in human cancer[J]. Nature, 2013, 500(7463): 415– 421. 23945592 PMC3776390
  76. [101]Snyder A, Makarov V, Merghoub T, Genetic basis for clinical response to CTLA-4 blockade in melanoma[J]. N Engl J Med, 2014, 371(23): 2189– 2199. 25409260 PMC4315319
  77. [104]Curran MA, Montalvo W, Yagita H, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J]. Proc Natl Acad Sci U S A, 2010, 107(9): 4275– 4280. 20160101 PMC2840093
  78. [105]Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy[J]. J Leukoc Biol, 2013, 94(1): 25– 39. 23625198 PMC3685017
  79. [108]Melero I, Shuford WW, Newby SA, Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors[J]. Nat Med, 1997, 3(6): 682– 685. 9176498
  80. [109]Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity[J]. Cancer Immunol Res, 2014, 2(2): 142– 153. 24778278 PMC4007342
  81. [110]Guo Z, Wang X, Cheng D, PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer[J]. PLoS One, 2014, 9(2): e89350. 24586709 PMC3937343
  82. [111]Kocak E, Lute K, Chang X, Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity[J]. Cancer Res, 2006, 66(14): 7276– 7284. 16849577
  83. [112]Belcaid Z, Phallen JA, Zeng J, Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model[J]. PLoS One, 2014, 9(7): e101764. 25013914 PMC4094423
  84. [113]Dai M, Wei H, Yip YY, Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation[J]. J Immunother, 2013, 36(4): 248– 257. 23603859 PMC3685275

Cited by

Sorted by citations

See all 119

Metadata

Authors
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W.
Venue
The Journal of Biomedical Research
Publisher
Journal of Biomedical Research
Published
2018
Volume
32
Issue
5
Pages
317
ISSN
1674-8301
DOI
10.7555/jbr.31.20160168
PMC
PMC6163118
Cited by
119
References
29

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune checkpoint inhibitors in cancer therapy. https://app.cochat.ai/papers/10.7555/jbr.31.20160168
The paper
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018). Immune checkpoint inhibitors in cancer therapy. The Journal of Biomedical Research. https://doi.org/10.7555/jbr.31.20160168